Pfizer reports 87% efficacy for its RSV vaccine in adults
Published June 23, 2022 | Originally published on Reuters Health Medical News
Pfizer’s respiratory syncytial virus (RSV) vaccine RSVpreF has an efficacy of 86.7% in healthy adults ages 18 to 50, according to results from a small phase 2a study published in Thursday’s New England Journal of Medicine.
Pfizer reports 87% efficacy for its RSV vaccine in adults | MDLinx